Neoadjuvant Alectinib in a Patient With Anaplastic Lymphoma Kinase (ALK)-Mutant Stage III Lung Adenocarcinoma: A Case Report – Cureus

Written by

admin

in

  1. Neoadjuvant Alectinib in a Patient With Anaplastic Lymphoma Kinase (ALK)-Mutant Stage III Lung Adenocarcinoma: A Case Report  Cureus
  2. ALEX Trial Final Results at ESMO 2025: Alectinib Demonstrates Durable Overall Survival and Long-Term Disease Control in Advanced ALK-Positive NSCLC  Oncodaily
  3. Study Investigates Alectinib Versus Crizotinib in the Adjuvant Setting for Patients With ALK+ NSCLC  Cancer Nursing Today
  4. Alecensa Improves 4-Year Survival in Early ALK-Positive Lung Cancer  Cure Today
  5. ‘Blow Your Mind’ Survival Improvement in Advanced, Mutated NSCLC  MedPage Today

Continue Reading

More posts